NanoViricides Inc - ESG Rating & Company Profile powered by AI
This assessment of NanoViricides Inc leverages intelligence from across the web as well as from public disclosures by NanoViricides Inc. This SDG assessment for NanoViricides Inc represents the company's reporting of the UN Sustainable Development Goals. If you work at NanoViricides Inc and you would like to use your Sustainability rating, please contact us.
NanoViricides Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.1; made up of an environmental score of 8.0, social score of 8.0 and governance score of 5.3.
7.1
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 217 | Takara Bio Inc | 7.2 | High |
| 217 | Ultragenyx Pharmaceutical Inc | 7.2 | High |
| 224 | NanoViricides Inc | 7.1 | High |
| 224 | Celularity Inc | 7.1 | High |
| 224 | Bilcare Ltd | 7.1 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does NanoViricides Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes NanoViricides Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes NanoViricides Inc report the average age of the workforce?
Sign up for free to unlockDoes NanoViricides Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes NanoViricides Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes NanoViricides Inc disclose cybersecurity risks?
Sign up for free to unlockDoes NanoViricides Inc offer flexible work?
Sign up for free to unlockDoes NanoViricides Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes NanoViricides Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes NanoViricides Inc conduct supply chain audits?
Sign up for free to unlockDoes NanoViricides Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes NanoViricides Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes NanoViricides Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes NanoViricides Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes NanoViricides Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes NanoViricides Inc disclose water use targets?
Sign up for free to unlockDoes NanoViricides Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid NanoViricides Inc have a product recall in the last two years?
Sign up for free to unlockDoes NanoViricides Inc disclose incidents of discrimination?
Sign up for free to unlockDoes NanoViricides Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas NanoViricides Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes NanoViricides Inc disclose parental leave metrics?
Sign up for free to unlockDoes NanoViricides Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes NanoViricides Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes NanoViricides Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes NanoViricides Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes NanoViricides Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes NanoViricides Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs NanoViricides Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes NanoViricides Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes NanoViricides Inc disclose its waste policy?
Sign up for free to unlockDoes NanoViricides Inc report according to TCFD requirements?
Sign up for free to unlockDoes NanoViricides Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes NanoViricides Inc disclose energy use targets?
Sign up for free to unlockDoes NanoViricides Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes NanoViricides Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for NanoViricides Inc
These potential risks are based on the size, segment and geographies of the company.
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Monkeypox Treatment for Monkeypox virus; Adenovirus 71 Treatment for severe pediatric hepatitis caused by Adenovirus 71 or related viruses; and HerpeCide Program Expansion Drug project that develops broad-spectrum nanoviricide drugs against different herpes viruses for different indications. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. The company was founded in 2005 and is based in Shelton, Connecticut.